CMS Decisions On New Off-Label Chemotherapy Compendia Due By Early July
Executive Summary
CMS will issue decisions by early July on the possible addition of four medical compendia as approved references for coverage of off-label uses of cancer drugs and biologicals
You may also be interested in...
DrugDex Endorsed As Off-Label Chemotherapy Guide For Medicare Coverage
CMS now recognizes Thomson Micromedex's DrugDex compendium as an authoritative reference for determining off-label coverage of cancer drugs under Medicare Part B, the agency announced June 10
DrugDex Endorsed As Off-Label Chemotherapy Guide For Medicare Coverage
CMS now recognizes Thomson Micromedex's DrugDex compendium as an authoritative reference for determining off-label coverage of cancer drugs under Medicare Part B, the agency announced June 10
CMS approves off-label chemotherapy compendium
CMS will recognize the National Comprehensive Cancer Network Drugs & Biologics Compendium as an approved reference for coverage of off-label uses of cancer drugs and biologics, the agency announces June 5. Local Medicare contractors who process claims for Part B, or physician-administered, drugs would consult the compendia when deciding whether to approve claims. CMS also announces it will formally delete from its list of recognized compendia the American Medical Association Drug Evaluations compendium, which ceased publication in 1996. The decisions represent a first step in CMS' efforts to update its compendia list; decisions in the coming weeks are expected on three other references - Gold Standard's Clinical Pharmacology and Thomson Micromedex's DrugPoints and DrugDex (1"The Pink Sheet" April 14, 2008, p. 15)